TS-075260 — Problem Type 2 diabetes and related metabolic disorders affect hundreds of millions of patients and are frequently accompanied by chronic inflammation, which accelerates disease progression and complications. Existing antidiabetic therapies often fail to adequately address inflammatory pathways and…

TS-075258 — PROBLEM Chronic heart failure following myocardial infarction (MI) afflicts ~6.7 million US adults and is driven by maladaptive immune activation, particularly persistent activation and proliferation of CD4+ T cells. Existing anti-inflammatory and immunomodulatory approaches have largely failed to …

TS-075254 — Problem Cardiomyopathy weakens the heart muscle and impairs its ability to pump blood effectively, often leading to heart failure or sudden cardiac death. While doxorubicin remains an essential component of many cancer regimens, its use is limited by the risk of causing lethal cardiomyopathy. A maj…

TS-075247 — PROBLEM Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ damage, affecting women at a 9:1 rate as compared to men. The etiology of SLE is complex and incompletely understood; however, the susceptibility of women during the years in which estrogen levels ar…

TS-075245 — Problem Although cyclin dependent kinase 9 (CDK9) is a promising drug target, traditional small-molecule inhibitors face challenges due to CDK9's structural similarities with other kinases, leading to off-target effects and limited efficacy Solution Applications Advantages Seeking opp…

TS-075240 — Problem Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with limited effective treatment options and a dismal prognosis. Current therapies often fail due to tumor resistance, poor specificity, and toxicity. The aggressive clinical behavior of LPS and its resistance to chem…

TS-075239 — Papaverine is an FDA-approved potent inhibitor of mitochondrial complex I. Papaverine’s mitochondrial complex I inhibition has been shown to be responsible for increased oxygenation and enhanced radiation response. However, papaverine is also a phosphodiesterase 10A (PDE10A) inhibitor with pot…

TS-075232 — Problem Breast cancer (BC) is the most commonly diagnosed malignancy and the second leading cause of cancer-related death among women in the United States. Within its subtypes, triple-negative breast cancer (TNBC) carries the highest mortality, driven in large part by a lack of effective targeted t…

TS-075231 — Problem Despite recent progress in cancer therapy, acquired resistance to existing cancer drugs reduces therapeutic efficacy. There is a strong need for a therapy with a novel mode of action to overcome drug resistance, and to improve therapeutic efficacy whether used alone or in combination therap…

TS-075186 — PROBLEM Exhausted CD8 T cells significantly limit the effectiveness of immunotherapies and cell therapies in cancer and chronic viral infections. Persistent antigen exposure drives durable epigenetic reprogramming that locks T cells into a dysfunctional state, silencing effector and memory-associat…